WILMINGTON, N.C. – Fred Eshelman, chairman and founder of Pharmaceutical Product Development (Nasdaq: PPDI), is reaching out to North Carolina executives to fill three board seats at the life science contract research company.

On Thursday, PPD said former Glaxo Chief Executive officer Robert Ingram and former Duke Health CEO Ralph Snyderman had been nominated to join the board. Vaughn Bryson, a former CEO at Eli Lilly, also was nominated.

Five of PPD’s existing board members, including Eshelman, would remain.

The board nominations will be considered at PPD’s annual meeting on May 18.

Ingram is a general partner at Hatteras Venture Partners and serves on several other boards.

Snyderman, an MD, is chairman emeritus and professor of medicine at Duke.

“Vaughn, Bob and Ralph will make great additions to our board of directors,” Eshelman said in a statement. “Each brings with him a unique set of skills and extensive leadership experience in areas key to the continued growth and success of our business. Vaughn and Bob bring a wealth of knowledge of the pharmaceutical industry, a key segment of our customer base, while Ralph brings with him not only a medical background, but also deep knowledge of drug development and large health care systems.”

For more details, read here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.